News

The U.S. Food and Drug Administration (FDA) recently approved a Supplemental New Drug Application (sNDA) for Boehringer Ingelheim Pharmaceuticals Inc.‘s Stiolto Respimat, adding data to the product’s labeling to reflect its demonstrated capacity to improve health-related quality of life in people with chronic obstructive pulmonary disease (COPD). Data came from Phase 3 clinical trials, OTEMTO…

The American Sleep Apnea Association (ASAA), a patient-led nonprofit organization to promote sleep health, has received approval from the Patient-Centered Outcomes Research Institute (PCORI)’s board of governors for a three-year, $2.5 million demonstration project into chronic obstructive pulmonary disease (COPD) and sleep apnea, called the O2VERLAP Study. The award for…

Boehringer Ingelheim Pharmaceuticals and Propeller Health are partnering to use digital health tools and services to help patients with asthma and chronic obstructive pulmonary disease (COPD) to better cope with their condition. Under the terms of the commercial agreement, people with asthma and COPD who are currently taking a Boehringer Ingelheim…

Verona Pharma, a clinical stage biopharmaceutical company focused on the development of therapeutic medicines to treat respiratory diseases, recently announced positive results of a Phase 2a dose-finding study on the new nebulized formulation of RPL554, its lead drug candidate. The positive data adds to the evidence that this drug could…

A decade-long follow-up study of more than 6,000 people who underwent heart computed tomography (CT) scans revealed that those with elevated coronary artery calcium scores might be at greater risk not only for heart and vascular disease, but also for cancer, chronic kidney disease, even chronic obstructive pulmonary disease (COPD). The study, “…

Sunovion Pharmaceuticals, a biopharma focused on the development of medical solutions for psychiatric, neurological, and respiratory conditions, recently presented the results of two clinical outcome research studies that investigated the treatment adequacy and inhaler use in chronic obstructive pulmonary disease (COPD) patients. The poster presentation sessions reporting data from…

Therabron Therapeutics, a biotech company developing a novel class of drugs based on the naturally occurring secretoglobin proteins, announced a new research program to develop a series of new isoforms of their lead candidate, the recombinant human CC10 protein. Therabron plans to provide treatment for a range of orphan and more commonplace…

A new study investigated the differences in the services provided to patients with chronic obstructive pulmonary disease (COPD) by doctors and by nurse practitioners and physician assistants. The study was conducted by researchers from The University of Texas Medical Branch (UTMB) at Galveston, and published in the scientific periodical PLOS…

Physical activity undertaken in small intervals spaced throughout the day can safely and markedly improve the health of people with chronic obstructive pulmonary disease (COPD) and other lung ailments, researchers in Australia reported, based on a review of COPD studies. Dr. Kylie Hill from the Curtin University led the research project,…

Propeller Health has partnered with Aptar Pharma, a drug delivery systems provider, for the development of technology based on metered dose inhaler systems (MDIs) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Under the terms of the partnership, Propeller and Aptar will work to develop the…